Background: Systemic sclerosis (SSc) is an autoimmune disease characterized by dysregulation of the immune system, vasculopathy and fibrosis of the skin and internal organs. Natural Killer (CD56 + CD3 -, NK) and NKT-like (CD56 + CD3 + ) cells display receptors (NKR) whose expression pattern determines their cytotoxic and immune-regulatory activity. The role of NK and NKT-like cells in the dysregulation of the immune system in SSc has not been fully elucidated yet. Objectives: To improve our knowledge on the contribution of NK, NKT-like and a subset of NKT cells expressing invariant TCR (iNKT) in SSc development, we performed a broad phenotyping of NKR in the circulation of SSc patients, including subjects with pre-clinical SSc. Methods: NKR were assessed by flow cytometry using two 13-color panels on whole blood of 84 SSc patients and 20 healthy controls (HC (col7) is the main component of the anchoring fibrils that connects the basement membrane to the underlying interstitial matrix and has mainly been investigated for its role in blistering skin diseases. It has been investigated for its role in dystrophic epidermolysis bullosa, a severe skin disease. Furthermore, increased levels of type VII collagen in skin has been reported for patients with systemic sclerosis (SSc). Objectives: The objective was to develop and characterize a blood-based marker assessing col7 degradation in patients with SSc. Methods: We identified a specific fragment of col7 in serum from COPD patients, which was not found in controls, using mass spectrometry. A monoclonal antibody was raised against the first ten amino acids of the neo-epitope (KLH-CGG-GPPGPPGRLV) and employed in a competitive ELISA (C7M). The C7M assay was validated technically and was subsequently evaluated in 2 cohorts including SSc patients. The first cohort (SSc#1; n=35) consisted of early (<2 years of SSc symptoms; n=16) and late (>10 years of disease with stable skin for at least 6 months, n=19) diffuse SSc patients, while the second cohort (SSc#2; n=119) consisted of limited (n=78) and diffuse (n=41) SSc patients. Serum C7M levels were likewise measured in healthy subjects and compared to the levels of SSc patients using the Kruskal-Wallis test with Dunn's multiple comparisons test comparing healthy individuals with the two SSc cohorts. Results: A technically robust competitive ELISA (C7M), which was highly specific for a col7 fragment was developed. The assay showed acceptable inter-(13%) and intra-assay (9%) variation, linearity (102% dilution recovery), analyte stability (102% recovery after 4 freeze/thaw cycles), and interference. The C7M marker was evaluated by comparing serum levels in healthy donors with patients with SSc ( Figure) . Serum C7M levels were not associated with age, gender, BMI, or disease duration. The geometric mean serum C7M level in healthy donors was 4.6 ng/mL (95% CI 3.7-5.6 ng/mL). The geometric mean serum C7M levels were significantly elevated in both cohorts of patients with SSc (SSc#1, 13.6 ng/mL [95% CI 11.1-16.5], p<0.0001; SSc#2, 9.2 ng/mL [95% CI 8.3-10.2], p<0.0001). Furthermore, a significant difference were observed between the two cohorts (P=0.05). Background: Idiopathic interstitial pneumonia (IIP) is characterized by an increased rate of extracellular matrix (ECM) turnover resulting in fibrosis. The pathogenic remodeling includes increased levels of protein synthesis and degradation mediated by proteases such as matrix metalloproteinases (MMPs). Acute exacerbations of IIP (AE-IIP) represent periods of increased disease activity. Pulmonary involvement, especially pulmonary fibrosis, is common in patients suffering from systemic sclerosis (SSc) and ankylosing spondylitis (AS) Objectives: The objective was to investigate if ECM remodeling was altered during AE-IIP by serological neo-epitope biomarkers. Methods: Serum samples were collected from patients with IIP at clinically stable disease (S-IIP, n=29) and at AE-IIP (n=68). Of these, 11 and 28 patients, respectively, had idiopathic pulmonary fibrosis (IPF). 28 IIP patients had paired samples. Biomarkers released from MMP-mediated degradation of collagen type I (C1M), III (C3M), IV (C4M), and VI (C6M), elastin (ELM7), versican (VCANM), biglycan (BGM), and C-reactive protein (CRPM) were assessed in serum by competitive ELISAs utilizing neo-epitope specific monoclonal antibodies. Data were analysed using Mann-Whitney test, Wilcoxon test, Spearman's rank correlation, and Kaplan-Meier curves as appropriate. Results: Mean age of patients was 71 (range 54-86) at AE-IIP and 69 (range 55-83) at S-IIP. Mean forced vital capacity in percentage of predicted value (%FVC) was 55.6% (SD 19.5) at AE-IIP and 79.0% (SD 26.5) at S-IIP. Serum levels of C4M, C6M, and CRPM at AE-IIP were positively correlated with %FVC (r=0.37, p=0.008; r=0.36, p=0.011; r=0.33, p=0.020; respectively) . Serum levels of C4M (p=0.002) and C6M (p=0.024) were increased while ELM7 (p=0.024) and VCANM (p<0.0001) were decreased at AE-IIP as compared with S-IIP when analyzing all patients. IPF patients had lower levels of VCANM at AE-IPF (p=0.0001). Patients with paired samples showed significantly elevated serum levels of C4M (p=0.004) and decreased levels of ELM7 and VCANM (p=0.036 and p=0.0001, respectively) at AE-IIP. C1M and C6M levels at AE-IIP were borderline related to mortality outcome for IPF patients (both p=0.059) with levels above median associated with a higher risk of mortality. Analyses of all or paired patients showed no associations with mortality. Conclusions: Serological levels of neo-epitope biomarkers of ECM degradation were associated with AE-IIP and weakly with mortality outcome. These results indicate that the rate of ECM remodeling in the lungs of patients with IIP is significantly altered during periods of high disease activity such as an acute exacerbation. The difference in degradation profile for the proteins studied is intriguing and indicate activation of different processes contributing to AE-IIP. Neo-epitope biomarkers of the ECM might be useful in identifying patients diagnosed with rheumatic disease as SSc and AS with pulmonary involvement. 
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